Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of medicines for serious, chronic conditions, particularly cardiometabolic diseases. The company's primary approved product is INPEFA (sotagliflozin), an oral medication indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Lexicon is currently conducting a Phase 3 clinical trial of sotagliflozin for hypertrophic cardiomyopathy and pursuing regulatory approval for ZYNQUISTA (sotagliflozin) as a treatment for type 1 diabetes. The company is also developing pilavapadin for neuropathic pain, having completed Phase 2 trials, and has licensed its obesity drug candidate LX9851 to Novo Nordisk for further development and commercialization. Lexicon utilizes a gene science approach based on Nobel Prize-winning technology to identify drug targets, having originated several of its candidates through internal discovery efforts and collaborations, including with Bristol-Myers Squibb. The company sells INPEFA in the United States through major and regional wholesalers.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lexpharma.com
Sector Healthcare IR page investors.lexpharma.com
Tags
cardiometabolic disease, heart failure, type 1 diabetes, hypertrophic cardiomyopathy, neuropathic pain, obesity, small molecule drugs, gene science, clinical trials, INPEFA, sotagliflozin, ZYNQUISTA, pilavapadin, LX9851, Novo Nordisk, Bristol-Myers Squibb, SONATA-HCM, PROGRESS, RELIEF-DPN-1, STENO1
Press page lexpharma.com/media-center/news

Metrics

Valuation  
Market cap $ 743.259M
Market cap (USD) $ 743.259M
P/E -11.92
PEG —
P/BV 4.54
P/S 19.29
P/OCF -15.10
P/FCF -10.95
Dividend yield —
Turnover / mcap —
Returns  
ROE -39.7%
ROI -31.2%
ROIC -22.7%
Profit margin -101.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 31.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 45
Quality score -40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 49.803M 6.001M 1.11M 0 0 23.404M 32.331M 26.583M 90.335M 83.337M 130.014M 22.854M 2.222M 1.089M 1.849M 4.908M 10.7M 32.321M 50.118M 72.798M 75.68M 61.74M 42.838M 35.2M 30.577M 14.459M
Net profit -50.341M -200.403M -177.119M -101.944M -87.758M -58.574M 130.133M -120.548M -129.05M -141.429M -4.682M -100.294M -104.126M -110.211M -116.215M -101.775M -93.317M -76.86M -58.794M -54.311M -36.315M -47.172M -64.198M -59.67M -35.172M -25.994M
Free cash flow -67.851M -179.811M -162.367M -90.177M -88.238M -143.056M 113.737M -148.702M -185.622M -175.859M 183.866M -75.702M -92.8M -94.952M -89.144M -83.5M -89.385M -97.787M -76.223M -60.488M 12.161M -54.067M -12.54M -10.655M -8.251M -5.089M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 1.15 0.74 1.53 1.91 3.94 3.42 4.15 6.64 9.88 13.83 13.31 0.91 1.8 2.21 — 1.15 1.57 3.8 2.98 — — — — — — —
Price performance 12m 0.56 -0.52 -0.2 -0.52 0.15 -0.18 -0.38 -0.33 -0.29 0.04 13.63 -0.49 -0.19 — — -0.27 -0.59 0.27 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 7.49M 4.83M 5.92M 56.5M 395,000 14,000 28,000 1.01M 3.47M 2.38M
↳ YoY growth +722.4% -35.6% +22.8% +854.3% -99.3% -96.5% +100.0% +3,507.1% +243.9% -31.4%
↳ 5y CAGR +84.5% +28.5% +49.6% +122.6% -15.4% -71.5% -64.3% -29.8% -42.8% +43.3%
Borrowings, current (USD) 16.3M 14.1M 1.12M 11M 11.6M 0.00 — — 0.00 4.6M
Borrowings, non-current (USD) 85.2M 232M 244M 234M 0.00 1.19M 5.42M 99.5M 100M 49.4M
Lease liabilities (USD) — — — 553,000 553,000 1.09M 1.29M 6.56M 5.78M 8.23M
Cash and deposits (USD) 46.6M 61.7M 80.4M 36.1M 126M 64.1M 46.3M 22.5M 66.7M 34.3M
Intangible assets (USD) 53.4M 23.2M 21.5M 19.7M — — — — — —
Right-of-use assets (USD) — — 2.1M 1.7M 1.2M 2.3M 6.8M 5.52M 4.83M 7.32M
Net debt (borrowings + leases - cash) (USD) 54.8M 184M 165M 209M -114M -61.8M -39.6M 83.6M 39.4M 27.9M
Cash flow detail
Operating cash flow (USD) -176M -185M -149M 114M -143M -87M -88.9M -162M -179M -67.9M
Purchases of property, plant and equipment (USD) -231,000 -228,000 -95,000 -70,000 -87,000 -1.22M -1.33M -470,000 -1.03M 0.00
Change in receivables (cash effect) (USD) -4.08M 166,000 -1.1M -50.6M 53.2M 381,000 -14,000 -982,000 -2.46M 1.09M
Change in inventories (cash effect) (USD) 0.00 -1.95M -2.73M 437,000 345,000 0.00 0.00 -381,000 150,000 -50,000
Change in payables (cash effect) (USD) -27.7M 7.17M -18.9M 20.1M -21M -14.2M 76,000 6.45M 14.8M -30.2M
Share buybacks (cash effect) (USD) -621,000 -1.68M -972,000 -941,000 -1.03M -2.68M -864,000 -824,000 -1.73M —
Interest paid (cash effect) (USD) -6.05M -5.87M -16.5M -19.2M -17.4M -799,000 -2.29M -10.1M -12.9M -8.33M
Share-based compensation (USD) 7.45M 9.47M 11.7M 14.2M 13.3M 10.6M 11.5M 14.3M 13.5M 12.5M
Operating cash flow before change in receivables (USD) -172M -186M -148M 164M -196M -87.4M -88.8M -161M -176M -68.9M
Free cash flow (OCF - PPE - intangibles) (USD) -176M -186M -149M 114M -143M -88.2M -90.2M -162M -180M -67.9M
Income detail
Research and development expense (USD) 178M 157M 100M 91.9M 154M 55M 52.8M 58.9M 84.5M 61.1M
↳ 5y CAGR +14.2% +13.7% +2.3% +0.6% +10.0% -20.9% -19.6% -10.1% -1.7% -16.8%
Total comprehensive income (USD) -141M -129M -120M 130M -58.7M -87.8M -102M -177M -200M -50.4M
Comprehensive income to owners (USD) -141M -129M -120M 130M -58.7M -87.8M -102M -177M -200M -50.4M
Reported Mar 1, 2018 Mar 1, 2018 May 1, 2019 Jul 29, 2020 Mar 12, 2021 Mar 10, 2022 Mar 3, 2023 Mar 25, 2024 May 14, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027

Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission

Phase 1 clinical development of LX9851 ongoing by Novo

Conference call and webcast at 8:30 am ET

THE WOODLANDS, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today reported financial results for the three months ended September 30, 2026, and provided an update on key corporate milestones and accomplishments.

“This quarter brought Lexicon into sharper focus as a cardiometabolic company and has positioned us to approach 2027 with strong momentum and multiple near-term potential catalysts and paths to value creation,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “Most notably, we completed enrollment in SONATA-HCM and are encouraged by the overall baseline characteristics of the study population, which we believe reflect a broad and clinically relevant spectrum of patients with symptomatic HCM. Together with our planned ZYNQUISTA NDA resubmission and the continued advancement of LX9851 by Novo, these achievements have positioned Lexicon for what we believe will be an important and catalyst-rich period for the company."

"As we prepare for several important milestones across our portfolio, we remain focused on investing prudently to support execution and position the Company for long-term success,” said Scott Coiante, Lexicon’s chief financial officer. “We believe our current financial position enables us to advance our key strategic priorities, including SONATA-HCM and the planned ZYNQUISTA NDA resubmission, while continuing to evaluate opportunities to unlock additional value across the portfolio."

Third Quarter 2026 Business and Pipeline Highlights

Sotagliflozin Sotagliflozin is a unique oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) and has been studied in approximately 20,000 patients across multiple cardiometabolic indications. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFA®.

Hypertrophic Cardiomyopathy (HCM)

  • Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study in patients with symptomatic obstructive (oHCM) and non-obstructive (nHCM) hypertrophic cardiomyopathy. The trial enrolled a total of 542 patients across both nHCM and oHCM, substantially exceeding its planned enrollment.

  • Baseline patient characteristics included demographics generally consistent with prior HCM studies of other agents, meaningful representation of both nHCM and oHCM patients and a mean baseline KCCQ-CSS of 59, reflecting considerable symptom burden at study entry. The primary efficacy endpoint will assess improvement in symptoms for the entire population.

  • Lexicon continues to expect topline results in the first quarter of 2027.

  • Two studies of sotagliflozin will be presented at the 2026 American Heart Association (AHA) Scientific Sessions in Chicago, November 6–9, providing new insights into its potential effects on thrombus formation as well as myocardial function in HCM, including findings from living human HCM heart tissue.

Type 1 Diabetes (T1D) (ZYNQUISTA**®****)**

  • Lexicon remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a patient population for which there are no treatment options beyond insulin.

  • STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) has achieved the patient exposure and safety data requirements agreed upon with the U.S. Food and Drug Administration (FDA) to support resubmission of the Company's New Drug Application (NDA).

  • Positive safety data showed low rates of DKA comparable to standard of care in STENO1, complementing the efficacy results in the Phase 3 inTandem program.

  • Data preparation and administrative work is now being completed to support a high-quality NDA resubmission, anticipated in the first quarter of 2027.

Viatris License for All Indications Ex-U.S. and Ex-Europe

  • Lexicon continues to support licensee Viatris in its regulatory filings and commercial strategy for sotagliflozin outside of the U.S. and Europe.

  • Viatris has obtained regulatory approval for heart failure in the United Arab Emirates and Bahrain and has submitted applications for regulatory approval for heart failure in several other markets, including Saudi Arabia, Canada, Australia, New Zealand, Mexico, Singapore, Oman, Thailand, Turkey, Malaysia, Philippines and Kuwait.

LX9851 LX9851 is a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) in development by licensee Novo for obesity and associated metabolic disorders.

Obesity and Associated Cardiometabolic Disorders

  • In March 2026, Novo initiated a Phase 1 study investigating single and multiple ascending doses of LX9851 compared to placebo in overweight or obese people.

  • In August 2026, Lexicon earned a third $10 million milestone payment in 2026 from Novo following the achievement of a key patient dosing milestone.

  • With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under the collaboration. Lexicon is also eligible for tiered royalties on net sales of LX9851.

Pilavapadin (LX9211)

Discovered using Lexicon’s unique approach to gene science and target identification, pilavapadin is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of adapter protein-2–associated kinase 1 (AAK1). Lexicon identified AAK1 as a promising approach for the treatment of neuropathic pain and is exploring its potential in other indications including obesity.

Diabetic Peripheral Neuropathic Pain (DPNP)

  • Pilavapadin has the potential to be the first oral, non-opioid drug therapy approved in neuropathic pain in more than 20 years.

  • Following the results of the Phase 2 PROGRESS study in 2025, the FDA has raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo. The primary endpoint of the Phase 3 studies would be the change in average daily pain score (ADPS) from baseline to Week 12.

Obesity and Additional Indications

  • Lexicon continues to explore additional indications for pilavapadin and recently generated preclinical data that demonstrates significant reduction in body weight from baseline when administered both as monotherapy and in combination with semaglutide.

  • Lexicon continues to explore strategic opportunities to maximize the global potential of this investigative therapy.

Third Quarter 2026 Financial Highlights

Revenues: Total revenues were $11.3 million for the third quarter of 2026, consisting primarily of $10.0 million of development milestone revenue from our license agreement with Novo and net sales of INPEFA of $1.2 million. Total revenues for the third quarter of 2025 were $14.2 million, consisting of $13.2 million of licensing revenue recognized from our license agreement with Novo and net sales of INPEFA of $1.0 million.

Research and Development (R&D) Expenses: Research and development expenses for the third quarter of 2026 decreased to $16.2 million from $18.8 million for the corresponding period in 2025, reflecting lower external research expenses due to completion of our PROGRESS Phase 2b clinical trial in 2025 partially offset by higher SONATA-HCM Phase 3 clinical trial expense in 2026.

Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the third quarter of 2026 increased to $9.5 million from $7.6 million for the corresponding period in 2025. The increase in 2026 reflects higher employee benefit costs and pre-commercialization expenses.

Net Loss: Net loss for the third quarter of 2026 was $14.0 million, or $0.03 per share, as compared to a net loss of $12.8 million, or $0.04 per share, in the corresponding period in 2025. For the third quarters of 2026 and 2025, net loss included non-cash, stock-based compensation expense of $3.4 million for each of the periods.

Cash, Investments and Restricted Cash: As of September 30, 2026, Lexicon had $183.2 million in cash and investments, as compared to $125.2 million in cash, investments, and restricted cash as of December 31, 2025. The increase in cash and investments primarily reflects net proceeds of $96.2 million from the sale of common and preferred stock in February 2026 partially offset by net cash used in operations.

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast today at 8:30 am ET / 7:30 am CT to review its financial and operating results and to provide a general business update. A live audio webcast of the call can be accessed by visiting the Events page of the Company’s investor relations website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the website for 30 days.

About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.

Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Media Inquiries: Dave Belian Lexicon Pharmaceuticals, Inc. [email protected]

For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. [email protected]

| Lexicon Pharmaceuticals, Inc. |

| Selected Financial Data |

| | | | | | | | | |

| Consolidated Statements of Operations Data | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| (In thousands, except per share data) | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| | | (Unaudited) | | (Unaudited) |

| Revenues: | | | | | | | | |

| Net product revenue | | $ | 1,181 | | | $ | 1,008 | | | $ | 2,951 | | | $ | 3,592 | |

| Licensing and milestone revenue | | | 10,000 | | | | 13,154 | | | | 30,000 | | | | 40,698 | |

| Royalties and other revenue | | | 69 | | | | 20 | | | | 93 | | | | 20 | |

| Total revenues | | | 11,250 | | | | 14,182 | | | | 33,044 | | | | 44,310 | |

| Operating expenses: | | | | | | | | |

| Cost of sales | | | 79 | | | | 10 | | | | 226 | | | | 73 | |

| Research and development, including stock-based | | | | | | | | |

| compensation of $1,424, $1,832, $4,177 and $5,026, respectively | | | 16,204 | | | | 18,757 | | | | 46,403 | | | | 49,806 | |

| Selling, general and administrative, including stock-based | | | | | | | | |

| compensation of $1,959, $1,612, $5,620 and $4,656, respectively | | | 9,462 | | | | 7,602 | | | | 28,446 | | | | 28,562 | |

| Total operating expenses | | | 25,745 | | | | 26,369 | | | | 75,075 | | | | 78,441 | |

| Loss from operations | | | (14,495 | ) | | | (12,187 | ) | | | (42,031 | ) | | | (34,131 | ) |

| Interest and other expense | | | (1,132 | ) | | | (2,155 | ) | | | (5,331 | ) | | | (6,308 | ) |

| Interest and other income | | | 1,622 | | | | 1,573 | | | | 4,888 | | | | 5,628 | |

| Loss on early extinguishment of debt | | | - | | | | - | | | | (4,349 | ) | | | - | |

| Net loss | | $ | (14,005 | ) | | $ | (12,769 | ) | | $ | (46,823 | ) | | $ | (34,811 | ) |

| | | | | | | | | |

| Net loss per common share, basic and diluted | | $ | (0.03 | ) | | $ | (0.04 | ) | | $ | (0.11 | ) | | $ | (0.10 | ) |

| | | | | | | | | |

| Weighted average common shares outstanding, basic and diluted | | | 444,956 | | | | 363,399 | | | | 427,780 | | | | 362,927 | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | As of | | As of | | | | |

| Consolidated Balance Sheet Data | | September 30, 2026 | | December 31, 2025 | | | | |

| (In thousands) | | | | | | | | |

| Cash and investments | | $ | 183,203 | | | $ | 96,230 | | | | | |

| Restricted cash | | | — | | | | 29,000 | | | | | |

| Property and equipment, net | | | 1,556 | | | | 1,863 | | | | | |

| Goodwill | | | 44,543 | | | | 44,543 | | | | | |

| Total assets | | | 242,021 | | | | 184,987 | | | | | |

| Current portion of long-term debt | | | — | | | | 4,595 | | | | | |

| Long-term debt, net | | | 51,894 | | | | 49,408 | | | | | |

| Accumulated deficit | | | (2,064,406 | ) | | | (2,017,583 | ) | | | | |

| Total stockholders' equity | | | 163,845 | | | | 107,538 | | | | | |

Search Investors

October 29, 2026

PDF Version

THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.

About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.

For Media Inquiries: Dave Belian Lexicon Pharmaceuticals, Inc. [email protected]

For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. [email protected]

Search Investors

October 23, 2026

PDF Version

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice --

-- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –

-- Substantial over enrollment strengthens statistical power and provides robust dataset to evaluate the efficacy and safety of sotagliflozin --

THE WOODLANDS, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3 SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM) clinical trial evaluating sotagliflozin in patients with symptomatic hypertrophic cardiomyopathy. The data will be presented in detail by Dr. Sharlene Day, M.D., Presidential Professor, Director of Translational Research of the Penn Cardiovascular Institute, University of Pennsylvania and co-chair of the SONATA-HCM steering committee, on Saturday, October 24, 2026, at 4:05 p.m. ET at the International HCM Summit in Boston, MA.

The patient enrollment profile of SONATA-HCM is consistent with the study’s inclusive design, which aimed to reflect real-world clinical practice. Patients were permitted to remain on stable background therapies, including cardiac myosin inhibitors, allowing evaluation of sotagliflozin in patients receiving currently available HCM treatments. Importantly, baseline demographic and clinical characteristics within both the non-obstructive (nHCM) and obstructive HCM (oHCM) cohorts were generally consistent with those reported in previous clinical studies of other agents in those respective patient populations, supporting the relevance of the SONATA-HCM study population to the broader HCM community.

In total, SONATA-HCM enrolled 542 patients across more than 130 sites in 20 countries, substantially exceeding the study’s target enrollment of 500 patients and a providing larger dataset that may further enhance the statistical power of the study to detect meaningful treatment effects on its primary efficacy endpoint. Among enrolled patients, 440 have nHCM and 102 have oHCM, positioning SONATA-HCM to evaluate sotagliflozin in a broad HCM population while emphasizing patients with non-obstructive disease, who currently have no FDA-approved disease-specific treatments.

The overall study population had a mean baseline Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) of 59, reflecting a considerable burden of symptoms and limitations in daily activities at study entry. KCCQ-CSS ranges from 0 to 100, with higher scores indicating better health status and fewer symptoms, demonstrating that the SONATA-HCM study population began the trial with substantial opportunity for improvement. The primary efficacy endpoint of the pivotal study is improvement in symptoms, as measured by change from baseline in KCCQ-CSS at Week 26.

"We designed SONATA-HCM to evaluate sotagliflozin in a broad and clinically relevant HCM population reflective of real-world clinical practice, and we are very pleased that the final study population met that objective," said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Lexicon. "The demographic and clinical characteristics of both the obstructive and non-obstructive HCM cohorts were generally consistent with those reported in previous studies of other agents, while the baseline KCCQ score reflects a population with meaningful symptom burden. Combined with the substantial over enrollment and representation of both major HCM subtypes, we believe SONATA-HCM is well positioned to evaluate sotagliflozin across the broad spectrum of symptomatic HCM patients."

SONATA-HCM is the only ongoing Phase 3 study in both nHCM and oHCM and is the largest Phase 3 study including both nHCM and oHCM to date. Topline results are anticipated in the first quarter of 2027.

About Sotagliflozin Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract and the heart. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for hypertrophic cardiomyopathy (HCM).

About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.

Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to the research, development and therapeutic and commercial potential of sotagliflozin in hypertrophic cardiomyopathy. In addition, this press release may also contain forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Media Inquiries: Dave Belian Lexicon Pharmaceuticals, Inc. [email protected]

For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. [email protected]

Search Investors

Prompts

Lexicon Pharmaceuticals, Inc. (ticker LXRX), listed in United States.

Company History

Date Change Detail
May 1, 2007 Renamed LEXICON GENETICS INC/TX → LEXICON PHARMACEUTICALS, INC./DE

ETFs Holding Lexicon Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
VFMO 0.06% 507,887 $ 1.143M Aug 31, 2026
RESM 0.02% 378 $ 907.20 Jun 30, 2026
MSSM 0.00% 14,755 $ 33.199K Aug 31, 2026